Endo at buy by Jefferies

Jefferies & Co., Inc. analyst David Windley rated Endo Pharmaceuticals Holdings Inc. at a buy. The analyst noted the complexity of the underlying issues in the Penwest dispute involving Opana ER. Opana ER is more important to Penwest, and the analyst believes the companies will attempt to resolve the matter through mediation itself, rather than costly binding arbitration. Shares of the Chadds Ford, Pa.-based biopharmaceutical company were down 10 cents, or 0.30%, at $33.20 on volume of 716,795 shares versus the three-month running average of 1,200,670 shares. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.